bioMerieux SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Pierre Boulud
- Full Time Employees
- 15,078
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 376 Chemin De l'Orme Marcy l'Etoile ARA France 69280
- IPO Date
- Jun 21, 2004
- Website
- biomerieux.com
- Similar Companies
- Business
- bioMérieux S.A. is a French multinational biotechnology company specializing in in vitro diagnostic solutions for infectious diseases, cancer screening, cardiovascular emergencies, and industrial applications such as food safety, pharmaceuticals, and cosmetics. Founded in 1963 and headquartered in Marcy-l'Étoile, France, bioMérieux designs, develops, manufactures, and markets diagnostic equipment, reagents, software, and services. Its core products include molecular biology solutions such as the BioFire FilmArray system, immunoassays, microbiology solutions like VIDAS, VITEK systems, and advanced point-of-care testing technologies including the SPOTFIRE platform. The company operates in over 44 countries and serves more than 160 countries worldwide through a large distribution network. Recent significant developments include the acquisition of Neoprospecta in early 2025, enhancing bioMérieux's Data & Genomics capabilities particularly in Brazil and Latin America for pathogen investigation and contamination prevention in food and pharmaceutical industries. It also acquired SpinChip Diagnostics in late 2025 to strengthen its point-of-care diagnostics portfolio with advanced immunoassay technology. bioMérieux launched the GENE-UP TYPER diagnostic solution for rapid root cause analysis of Listeria monocytogenes contamination in food industries and the WatchFire molecular PCR test for detecting viruses and bacteria in wastewater. Furthermore, the company signed an exclusive worldwide distribution agreement with Oxford Nanopore Technologies for the AmPORE TB® assay, a molecular sequencing test addressing Mycobacterium tuberculosis and antimicrobial resistance detection. In 2024, bioMérieux received multiple FDA approvals including for its BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini, enabling rapid multiplex PCR-based diagnostics with CLIA-waiver for point-of-care use. The company pursued its GO- 28 strategic plan focusing on innovation, achieving double-digit organic sales growth driven by microbiology reagents, non-respiratory and respiratory BIOFIRE panels, and expanded industrial application sales. bioMérieux continues to drive development in molecular diagnostics, immunoassays, software, and integrated diagnostic systems while maintaining a robust global commercial infrastructure and innovation pipeline in infectious disease diagnostics and industrial microbiology safety solutions.
Company News
bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – What’s Next?
bioMerieux (OTCMKTS:BMXMF) Stock Now Rated “Reduce” by Sell-Side Analysts
bioMérieux S.A. (BMXXY) Q1 2026 Sales/Trading Call Transcript
Analyzing HealthEquity (NASDAQ:HQY) and bioMerieux (OTCMKTS:BMXMF)
bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Time to Buy?
bioMérieux S.A. (BMXXY) Q4 2025 Earnings Call Transcript
bioMerieux (OTCMKTS:BMXMF) Sees Unusually-High Trading Volume – Time to Buy?
bioMérieux S.A. (BMXXY) Analyst/Investor Day Transcript
bioMérieux S.A. (BMXMF) Q4 2024 Earnings Call Transcript
bioMérieux S.A. (BMXMF) Q2 2024 Earnings Call Transcript
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript
bioMérieux: Pioneering In Vitro Diagnostics
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript
4 Top Medical Services Stocks to Beat COVID-19 Resurgence Crisis